| Literature DB >> 15475754 |
Mimouna Seddik1, Hugues Meliez, David Seguy, Nathalie Viget, Antoine Cortot, Jean Frederic Colombel.
Abstract
Anti-TNFalpha therapy is an effective treatment of Crohn's disease. There is an increased risk of infection, including atypical infection associated in infliximab treated patients. We report a case of a young man who developed Pneumocystisjiroveci pneumonia shortly after starting therapy with infliximab. Thus, although rare, prophylaxis against Pneumocystis jiroveci pneumonia might be considered when starting a treatment with infliximab, especially in patients receiving concomitant immunosuppressive agents.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15475754 DOI: 10.1097/00054725-200407000-00017
Source DB: PubMed Journal: Inflamm Bowel Dis ISSN: 1078-0998 Impact factor: 5.325